July 6, 2021 08:44 AM EDTUpdated 01:59 PM

Chinese health authority erects new gold standard in oncology R&D, spooking investors in booming field

Kyle Blankenship

The US has long been the leader in research and development in oncology, but homegrown Chinese drugmakers have jumped one hurdle after another in making …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chinese health authority erects new gold standard in oncology R&D, spooking investors in booming field

Kyle Blankenship

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

Chi­nese health au­thor­i­ty erects new gold stan­dard in on­col­o­gy R&D, spook­ing in­vestors in boom­ing field

Kyle Blankenship

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Chinese health authority erects new gold standard in oncology R&D, spooking investors in booming field

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus